Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue.
Identifieur interne : 004897 ( Main/Exploration ); précédent : 004896; suivant : 004898Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue.
Auteurs : RBID : pubmed:7908220English descriptors
- KwdEn :
- Adult, Aged, Carcinoma, Small Cell (radionuclide imaging), Cerebellar Neoplasms (radionuclide imaging), Cerebellar Neoplasms (secondary), Female, Humans, Indium Radioisotopes (diagnostic use), Lung Neoplasms (radionuclide imaging), Male, Middle Aged, Neoplasm Metastasis (radionuclide imaging), Neoplasm Recurrence, Local (radionuclide imaging), Somatostatin (analogs & derivatives), Somatostatin (diagnostic use).
- MESH :
- chemical , analogs & derivatives : Somatostatin.
- chemical , diagnostic use : Indium Radioisotopes, Somatostatin.
- radionuclide imaging : Carcinoma, Small Cell, Cerebellar Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local.
- secondary : Cerebellar Neoplasms.
- Adult, Aged, Female, Humans, Male, Middle Aged.
Abstract
Recent work suggests that between 50 and 75% of small-cell lung cancer (SCLC) tumours have specific high-affinity binding sites for somatostatin. This study evaluated the potential role of the radiolabelled somatostatin analogue, [111In]pentetreotide, in the detection and staging of SCLC in patients prior to and after chemotherapy using scintigraphic imaging techniques. Thirteen patients were studied prior to chemotherapy. Following standard staging six patients had limited stage disease and seven extensive disease. [111In]pentetreotide imaging led to the detection of all primary sites of disease, including a primary site of disease not detectable with chest radiograph or computerised tomography (CT) of the thorax. Five of ten metastatic sites detected by standard staging were also imaged. Furthermore, a cerebellar metastasis was detected in a patient thought to have disease confined to the right hemithorax. This was subsequently confirmed with a CT brain scan. Following chemotherapy [111In]pentetreotide imaging detected residual intrathoracic disease in two of three patients with complete remissions by standard staging and in two patients who had had a partial response to chemotherapy. These results suggest that [111In]pentetreotide imaging may have a role to play in the clinical evaluation of patients with SCLC. Specifically, this technique may be of particular value in detecting residual intrathoracic disease in patients thought to be in complete remission by conventional staging methods.
PubMed: 7908220
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue.</title><author><name sortKey="O Byrne, K J" uniqKey="O Byrne K">K J O'Byrne</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, Mater Misericordiae Hospital, Dublin, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>Department of Oncology, Mater Misericordiae Hospital, Dublin</wicri:regionArea></affiliation></author><author><name sortKey="Ennis, J T" uniqKey="Ennis J">J T Ennis</name></author><author><name sortKey="Freyne, P J" uniqKey="Freyne P">P J Freyne</name></author><author><name sortKey="Clancy, L J" uniqKey="Clancy L">L J Clancy</name></author><author><name sortKey="Prichard, J S" uniqKey="Prichard J">J S Prichard</name></author><author><name sortKey="Carney, D N" uniqKey="Carney D">D N Carney</name></author></titleStmt><publicationStmt><date when="1994">1994</date><idno type="RBID">pubmed:7908220</idno><idno type="pmid">7908220</idno><idno type="wicri:Area/Main/Corpus">004D04</idno><idno type="wicri:Area/Main/Curation">004D04</idno><idno type="wicri:Area/Main/Exploration">004897</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Carcinoma, Small Cell (radionuclide imaging)</term><term>Cerebellar Neoplasms (radionuclide imaging)</term><term>Cerebellar Neoplasms (secondary)</term><term>Female</term><term>Humans</term><term>Indium Radioisotopes (diagnostic use)</term><term>Lung Neoplasms (radionuclide imaging)</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Metastasis (radionuclide imaging)</term><term>Neoplasm Recurrence, Local (radionuclide imaging)</term><term>Somatostatin (analogs & derivatives)</term><term>Somatostatin (diagnostic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Somatostatin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Indium Radioisotopes</term><term>Somatostatin</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Carcinoma, Small Cell</term><term>Cerebellar Neoplasms</term><term>Lung Neoplasms</term><term>Neoplasm Metastasis</term><term>Neoplasm Recurrence, Local</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Cerebellar Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Recent work suggests that between 50 and 75% of small-cell lung cancer (SCLC) tumours have specific high-affinity binding sites for somatostatin. This study evaluated the potential role of the radiolabelled somatostatin analogue, [111In]pentetreotide, in the detection and staging of SCLC in patients prior to and after chemotherapy using scintigraphic imaging techniques. Thirteen patients were studied prior to chemotherapy. Following standard staging six patients had limited stage disease and seven extensive disease. [111In]pentetreotide imaging led to the detection of all primary sites of disease, including a primary site of disease not detectable with chest radiograph or computerised tomography (CT) of the thorax. Five of ten metastatic sites detected by standard staging were also imaged. Furthermore, a cerebellar metastasis was detected in a patient thought to have disease confined to the right hemithorax. This was subsequently confirmed with a CT brain scan. Following chemotherapy [111In]pentetreotide imaging detected residual intrathoracic disease in two of three patients with complete remissions by standard staging and in two patients who had had a partial response to chemotherapy. These results suggest that [111In]pentetreotide imaging may have a role to play in the clinical evaluation of patients with SCLC. Specifically, this technique may be of particular value in detecting residual intrathoracic disease in patients thought to be in complete remission by conventional staging methods.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">7908220</PMID><DateCreated><Year>1994</Year><Month>05</Month><Day>04</Day></DateCreated><DateCompleted><Year>1994</Year><Month>05</Month><Day>04</Day></DateCompleted><DateRevised><Year>2013</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-0920</ISSN><JournalIssue CitedMedium="Print"><Volume>69</Volume><Issue>4</Issue><PubDate><Year>1994</Year><Month>Apr</Month></PubDate></JournalIssue><Title>British journal of cancer</Title><ISOAbbreviation>Br. J. Cancer</ISOAbbreviation></Journal><ArticleTitle>Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue.</ArticleTitle><Pagination><MedlinePgn>762-6</MedlinePgn></Pagination><Abstract><AbstractText>Recent work suggests that between 50 and 75% of small-cell lung cancer (SCLC) tumours have specific high-affinity binding sites for somatostatin. This study evaluated the potential role of the radiolabelled somatostatin analogue, [111In]pentetreotide, in the detection and staging of SCLC in patients prior to and after chemotherapy using scintigraphic imaging techniques. Thirteen patients were studied prior to chemotherapy. Following standard staging six patients had limited stage disease and seven extensive disease. [111In]pentetreotide imaging led to the detection of all primary sites of disease, including a primary site of disease not detectable with chest radiograph or computerised tomography (CT) of the thorax. Five of ten metastatic sites detected by standard staging were also imaged. Furthermore, a cerebellar metastasis was detected in a patient thought to have disease confined to the right hemithorax. This was subsequently confirmed with a CT brain scan. Following chemotherapy [111In]pentetreotide imaging detected residual intrathoracic disease in two of three patients with complete remissions by standard staging and in two patients who had had a partial response to chemotherapy. These results suggest that [111In]pentetreotide imaging may have a role to play in the clinical evaluation of patients with SCLC. Specifically, this technique may be of particular value in detecting residual intrathoracic disease in patients thought to be in complete remission by conventional staging methods.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>O'Byrne</LastName><ForeName>K J</ForeName><Initials>KJ</Initials><Affiliation>Department of Oncology, Mater Misericordiae Hospital, Dublin, Ireland.</Affiliation></Author><Author ValidYN="Y"><LastName>Ennis</LastName><ForeName>J T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Freyne</LastName><ForeName>P J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Clancy</LastName><ForeName>L J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Prichard</LastName><ForeName>J S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Carney</LastName><ForeName>D N</ForeName><Initials>DN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Case Reports</PublicationType><PublicationType>Clinical Trial</PublicationType><PublicationType>Journal Article</PublicationType><PublicationType>Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>SCOTLAND</Country><MedlineTA>Br J Cancer</MedlineTA><NlmUniqueID>0370635</NlmUniqueID><ISSNLinking>0007-0920</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>138661-02-6</RegistryNumber><NameOfSubstance>pentetreotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>51110-01-1</RegistryNumber><NameOfSubstance>Somatostatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Peptides. 1991 Jul-Aug;12(4):839-43</RefSource><PMID Version="1">1686316</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Thorax. 1991 Nov;46(11):843-50</RefSource><PMID Version="1">1663276</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1992 Apr 4;339(8797):846-9</RefSource><PMID Version="1">1347865</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 1992 May;33(5):652-8</RefSource><PMID Version="1">1349039</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 1992 Jun 1;52(11):3089-93</RefSource><PMID Version="1">1317257</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Metabolism. 1992 Sep;41(9 Suppl 2):83-6</RefSource><PMID Version="1">1355591</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 1993 Jan;83(1):75-9</RefSource><PMID Version="1">8094627</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Nucl Med. 1993 Aug;20(8):716-31</RefSource><PMID Version="1">8404961</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 1990 Jul 15;50(14):4360-5</RefSource><PMID Version="1">1973071</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Endocrinol Metab. 1990 Sep;71(3):566-74</RefSource><PMID Version="1">2168430</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Metabolism. 1990 Sep;39(9 Suppl 2):78-81</RefSource><PMID Version="1">2169575</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1990 Nov 1;323(18):1246-9</RefSource><PMID Version="1">2170840</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 1990 Oct;62(4):684-6</RefSource><PMID Version="1">2171623</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 1990 Nov 15;66(10):2129-33</RefSource><PMID Version="1">2171745</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 1991 Jan 16;83(2):78-9</RefSource><PMID Version="1">1988690</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 1991 Sep;64(3):451-6</RefSource><PMID Version="1">1654981</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 1991 Oct;32(10):1845-8</RefSource><PMID Version="1">1655997</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocrinology. 1982 Oct;111(4):1394-6</RefSource><PMID Version="1">6126353</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1983 Jan 1;1(8314-5):65</RefSource><PMID Version="1">6129392</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1983 Dec 15;309(24):1495-501</RefSource><PMID Version="1">6139753</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1983 Dec 22;309(25):1556-63</RefSource><PMID Version="1">6140639</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Life Sci. 1985 Jul 15;37(2):105-13</RefSource><PMID Version="1">2409423</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 1985 Aug 29-Sep 4;316(6031):823-6</RefSource><PMID Version="1">2993906</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Immunol Immunopathol. 1986 Nov;41(2):290-4</RefSource><PMID Version="1">2876793</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Radiology. 1987 Nov;165(2):297-304</RefSource><PMID Version="1">3498971</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunology. 1987 Dec;62(4):655-8</RefSource><PMID Version="1">2892785</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochem Biophys Res Commun. 1988 May 31;153(1):81-6</RefSource><PMID Version="1">2897854</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cancer Res Clin Oncol. 1988;114(3):235-44</RefSource><PMID Version="1">2838487</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Life Sci. 1988;43(5):421-7</RefSource><PMID Version="1">2899828</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 1989 Jan 15;264(2):949-52</RefSource><PMID Version="1">2562957</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1989 Feb 4;1(8632):242-4</RefSource><PMID Version="1">2563413</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunopharmacology. 1989 Jan-Feb;17(1):45-9</RefSource><PMID Version="1">2565322</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 1990 Feb 15;45(2):269-74</RefSource><PMID Version="1">1968052</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 1990 Apr 15;50(8):2511-7</RefSource><PMID Version="1">2156621</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Invest. 1991;9(6):659-73</RefSource><PMID Version="1">1684134</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1992 Apr 4;339(8797):843-6</RefSource><PMID Version="1">1347864</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Carcinoma, Small Cell</DescriptorName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Cerebellar Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="N">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasm Metastasis</DescriptorName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Somatostatin</DescriptorName><QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC1968808</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7908220</ArticleId><ArticleId IdType="pmc">PMC1968808</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004897 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004897 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:7908220
|texte= Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:7908220" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |